Opportunity Assessment
In preparation for their innovative radiopharmaceutical asset entering in-person clinical studies, a NASDAQ listed Biotech wanted to understand both the commercial and clinical potential of their asset in a variety of solid, non-resectable tumors and align on lead indication(s) for their biomarker-targeted therapy
Differentiated Integrated Evidence Plan
Our client did not have a sufficient evidence plan place in place which resulted in numerous evidence gaps and it falling short in its ability to articulate the unmet need, especially with regards to required HEOR and medical evidence
Market Landscape Assessment
Our client, a global pharma company and market leader grossing >$3Bn annually, was facing Loss of Exclusivity for its anti-VEGF therapy in all key markets and faced significant competition from new-entrants and biosimilars
LoE Strategy
Our client, a global pharma company and market leader grossing >$3Bn annually, was facing Loss of Exclusivity for its anti-VEGF therapy in all key markets and faced significant competition from new-entrants and biosimilars
Elevating Outcomes with AI
Our client was preparing to launch their first asset in the Immunology TA, and understood that the care pathway had many inflection points and data capture opportunities across the patient journey
